Výsledky vyhledávání

Phase 2 Study of Second-Line Dovitinib (Tki258) in Patients with Fibroblast Growth Factor Receptor 2 (Fgfr2)-Mutated or -Nonmutated Advanced and/or Metastatic Endometrial Cancer

Autor: P.C. Fong, Kaushal Mishra, N. Finkler, Paula S. Lee, Rebecca Kristeleit, Y.A. Wang, Matthew Squires, Allison Upalawanna, Gottfried E. Konecny, Domenica Lorusso, A. A. Garcia, Rodney P. Rocconi

Publikováno v: Annals of Oncology. 25:v1

Aim: Activating mutations in FGFR2, identified in 10%-15% of primary endometrial cancers (ECs), are associated with disease progression and poor outcome. Here, we evaluate dovitinib, a potent tyrosine kinase inhibitor of FGFR, VEGFR, and PDGFR, as se

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f75d52888397a06a1be3e568f14b6598
https://doi.org/10.1093/annonc/mdu438.28

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Single agent, canfosfamide (C, TLK286) vs pegylated liposomal doxorubicin (D) or topotecan (T) in 3rd-line treatment of platinum (P) refractory or resistant ovarian cancer (OC): Phase 3 study results

Autor: S. B. Kaye, J. Hunter, J. M. Del Campo, David R. Spriggs, N. Finkler, A. Lohr, John J. Kavanagh, Daniela Matei, Gail L. Brown, Ignace Vergote, Jan B. Vermorken

Publikováno v: Journal of Clinical Oncology. 25:LBA5528-LBA5528

LBA5528 Background: Canfosfamide (C) is a novel glutathione analog prodrug activated by glutathione S-transferase P1–1. P resistant OC has a poor prognosis and non-P agents are used for palliation. C reported objective responses in multicenter Phas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fd4322ca806a4caf85986ba02fd8caac
https://doi.org/10.1200/jco.2007.25.18_suppl.lba5528

Zobrazit plný text záznamu

Phase 3 Study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC)

Autor: Tatjana Kolevska, Carolyn N. Krasner, Linda R. Duska, N. Finkler, Peter G. Rose, E. Brand, C. Runowicz, Michael V. Seiden, Robert Edwards, Gail L. Brown, F. Cappuccini

Publikováno v: Journal of Clinical Oncology. 25:LBA5529-LBA5529

LBA5529 Background: Canfosfamide (C) is a novel glutathione analog prodrug activated by glutathione S-transferase P1–1. C has single agent activity in P resistant OC and is synergistic with P. Methods: Pts with P resistant OC following ≤ 2 P regi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::abfe793f385ea4b8792fbd18884d6019
https://doi.org/10.1200/jco.2007.25.18_suppl.lba5529

Zobrazit plný text záznamu

Use of thalidomide as consolidation therapy in ovarian and primary peritoneal cancers

Autor: B. Ndubisi, F. Ciricano, N. Finkler

Publikováno v: Journal of Clinical Oncology. 22:5154-5154

5154 Background: Ovarian cancer represents 55% of all gyn cancer deaths. Over 70% are Diagnosed at stage III and IV with survival of 0 to 30%. Response rates of 70 to 80% and median survival of 38 ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6381d7b73c7628cdc0b08a4cc3eb3d4f
https://doi.org/10.1200/jco.2004.22.90140.5154

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání